Holger Neecke

Is Director of Business Development at Adare Pharmaceuticals in Milan, a specialty CDMO business science-driven provider of dosage form solutions for the healthcare industry. He joined Adare Pharmaceuticals in 2015 and is Responsible for Business Development world-wide (excluding North America)

In 2001 he worked as Director BD & Investor Relations at MolMed S.p.A., a clinical-stage biotech company developing novel therapies against cancer and listed on the Milan Stock Exchange.

He has acquired a broad expertise in biotech business development, particularly by:
• structuring, negotiating and finalising all contracts (research, license, collaboration, clinical trials, services) above €10’000, including important license agreements with research institutions and pharma/biotech companies in Europe, Japan and the U.S.
• assessing market potential of products and performing DCF-based portfolio analysis
• leading the project management of clinical-stage products

Holger Neecke was also responsible for MolMed’s Investor Relations, representing the company in roadshows and at investor meetings, and defining the annual IR communication plan. He was lecturer of a 16-hours course in Business Strategy at the Univerisity “Vita-Salute San Raffaele” School of Medicine (course in Medical and Pharmaceutical Biotechnology).

Before joining MolMed, Holger Neecke worked at Biopolo Scrl, a biotech transfer agencies in Milan, where he developed and evaluated business plans for start-up companies.

Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics from the University of Milan, and a MBA from SDA Bocconi Business School, Milan.